InvestmentApr 27, 2026, 04:18 PM
ORKA Commences $500M Public Offering of Stock & Warrants
AI Summary
Oruka Therapeutics, Inc. announced the commencement of an underwritten public offering to raise $500 million. The offering consists of shares of its common stock and pre-funded warrants. Additionally, the company expects to grant the underwriters a 30-day option to purchase up to an additional $75 million of common stock. The proposed offering is subject to market and other conditions.
Key Highlights
- Oruka Therapeutics commenced an underwritten public offering to raise $500 million.
- The offering includes shares of common stock and pre-funded warrants.
- Underwriters have a 30-day option to purchase up to an additional $75 million in common stock.
- Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim Securities are joint bookrunning managers.
- A shelf registration statement on Form S-3 became effective on April 10, 2026.